-- Margaret Farley Steele
THURSDAY, Sept. 12 (HealthDay News) -- U.S. advisers endorsed on
Thursday the broader use of a drug already used to treat advanced
breast cancer that also appears to shrink early stage breast
This could potentially offer women with early stage breast
cancer a first-of-its-kind treatment option and the hope of
less-invasive surgical procedures.
If approved to treat early stage tumors, the drug, Perjeta,
might result in less invasive surgical treatment for women with
HER2-positive early stage breast cancer. In that role, Perjeta
(pertuzumab) would be the first cancer-fighting drug approved as a
first-step breast cancer therapy in the United States.
A U.S. Food and Drug Administration advisory panel voted 13 to 0
to recommend approval of the drug. The FDA is not bound to follow
the recommendations of its advisory panels but it usually does.
An FDA report that was posted online Tuesday said the drug
looked promising in trials. The report also said, however, that
drug-related cardiac concerns will require additional research.
Advisory panel chairman Dr. Mikkael Sekeres, a professor of
medicine at the Cleveland Clinic, called Thursday's vote "a
The Associated Pressreported.
"We are supporting the movement of a highly active drug for metastatic breast cancer to the first-line setting, with the hope that women with earlier stages of breast cancer will live longer and better," Sekeres said.
The FDA is considering "fast-track" -- or accelerated --
approval of Perjeta, which is made by Roche's Genentech division,
the APreported. Fast-track approvals usually are given to
drugs that haven't been thoroughly tested but show promising
results in early trials.
Panel members insisted Thursday that Genentech carry out more
trials to ensure that Perjeta will enable breast cancer patients to
live longer, healthier lives, the news service said.
Genentech estimated that about 15,000 women with HER2-positive
early stage breast cancer could receive early treatment with
Perjeta each year,
Cancer specialists welcomed the news earlier this week of the
preliminary results for Perjeta.
"This is tremendously exciting," said Dr. Amy Tiersten, associate professor in the division of hematology and medical oncology at Mount Sinai Medical Center in New York City.
"Pertuzumab was FDA approved in 2012 for the treatment of metastatic breast cancer when it was shown that it improved survival when added to standard regimens for HER2-positive metastatic breast cancer," Tiersten said. Metastatic breast cancer is cancer that has spread to other parts of the body.
"But the really exciting information is when this can be translated into earlier stages of disease, where we can completely eradicate the disease and cure more women," she said.
The preliminary trial under discussion showed that when Perjeta
was added to standard pre-surgical regimens for HER2-positive
breast cancer, the chance of finding no cancer after the treatment
was nearly doubled, Tiersten said.
Women who have chemotherapy before surgery and who achieve
complete remission -- no cancer at the time of breast surgery --
have a much greater chance of being completely cured of their
disease, she said.
Dr. Aye Moe Thu Ma, attending physician in breast surgical
oncology with St. Luke's and Roosevelt Hospitals in New York City,
also voiced enthusiasm.
"We currently have limited options for [first-step] treatment of breast cancer," Ma said. "I'm excited that this may provide a more specific treatment for people with HER2-positive cancer."
This means women may be able to keep their breasts because the
tumor size is reduced before surgery, and some women may prefer
this, she said.
Genentech is hoping for fast-track approval of Perjeta. The FDA
can expedite approval for groundbreaking drugs as long as the drug
maker pursues more research to show that the medication prolongs
Both short- and long-term side effects will need to be examined
to fully evaluate risks and benefits of this medication if it is
approved, Ma added.
Perjeta is one of many newer biologic agents used to treat
breast cancer. "These biologic or 'targeted' treatments work on
breast cancer cells in a more specific way than some older
treatments so there are many fewer casualties to normal cells
translating into many fewer side effects for our patients,"
About one in eight women in the United States will develop
breast cancer in her lifetime.
According to the Mayo Clinic, HER2-positive breast cancer is a
breast cancer driven by a protein called human epidermal growth
factor receptor 2 (HER2), which promotes the growth of cancer
HER2-positive breast cancers typically are more aggressive than
other types of breast cancer. But there are effective drug
treatments, including trastuzumab (brand name Herceptin) and
lapatinib (Tykerb). Both drugs can produce side effects, including
congestive heart failure, according to the Mayo Clinic.
The U.S. Department of Health and Human Services has more about
early stage breast cancer.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.